Genomics – Thematic Intelligence

Genomics Market Thematic Report Overview

Genomics refers to the study of an entire set of DNA within an organism. This includes researching their molecular components, structures, and functions of genes, and developing technologies that map and edit sequences of DNA. Direct-to-consumer genetic testing (DTC-GT) has been a rapidly expanding market that continues to generate substantial amounts of revenue and public interest. The rapid growth of the market has historically been accompanied by regulatory limitations on the extent of consumer health information these services can provide.

The genomics market thematic intelligence report is a thematic brief, which identifies those companies most likely to succeed in a world filled with disruptive threats. Inside, we predict how each theme will evolve and identify the leading and disrupting companies.

Genomics-Key Trends

The main trends shaping the genomics industry are classified into technology trends, macroeconomic trends, and regulatory trends.

Technology Trends: The key technology trends impacting the theme are the switch from using the Illumina OmniExpress chip to a customized Illumina global screening array (GSA) microarray, the shift from SNP-BeadArray chips to NGS, the role of social media, privacy, and security concerns, and result accuracy. For instance, one of the most popular SNP-BeadArray devices previously utilized by DTC-GT companies is the Illumina OmniExpress chip. This product was employed by 23andMe, Ancestry.com, MyHeritage, and FamilyTreeDNA. In 2017, 23andMe switched from using the Illumina OmniExpress chip to a customized Illumina Global Screening Array (GSA) microarray. More recently, MyHeritage, and FamilyTreeDNA also switched to using the newer GSA product. It should be noted that MyHeritage DNA samples are processed in the FamilyTreeDNA laboratory, meaning that the two companies are linked in terms of the underlying technology.

Macroeconomic Trends: The impact of COVID-19 pandemic and the growing pace of mergers & acquisitions in the genomics landscape are the key macroeconomic trends explained in the report.

Regulatory Trends: The key regulatory trends explained in the report are, FDA classified DTC- GTs as class II medical devices, Laboratory- developed tests (LDTs) sold with physician oversight, FDA exempts subsequent genetic testing devices from 510(k) premarket approval, FDA exempts subsequent genetic testing devices from 510(k) premarket approval, and Genetic Information Nondiscrimination Act, US.

Genomics Value Chain Analysis

The genomics value chain comprises of three different components: the underlying technology, DTC-GT service providers and third party re-analysis of individuals’ generic information.

The technology underlying this market consists primarily of SNP-BeadArray chips, with DNA collection tubes and next- generation sequencing reagents also being important factors.

Most of these products are sold as class II medical devices, laboratory-developed tests, or do not require FDA premarket approval. As such, pre-clinical/clinical trials are not needed and there are fewer regulatory barriers to market access. DTC-GT service providers perform analysis across a range of different market sectors such as genetic health risks, carrier screening, traits and wellness, and ancestry.

Genomics Value Chain Analysis

For more insights on the genomics value chain, download a free report sample

Leading Public Companies in the Genomics Theme

Some of the leading public companies in the genomics theme are:

• 23andMe
• Illumina
• OraSure Technologies
• Qiagen
• Thermo Fisher Scientific

Leading Private Companies in the Genomics Theme

Some of the leading private companies in the genomics theme are:

• com
• FamilyTreeDNA
• Helix OpCo
• LiveWello
• MyHeritage
• Orig3N
• Pathway Genomics

For more insights on the public and private companies impacting the genomics theme, download a free report sample

Medical Devices Sector Scorecard

At GlobalData, we use a scorecard approach to predict tomorrow’s leading companies within each sector. Our sector scorecard has three screens: a thematic screen, a valuation screen, and a risk screen.

• The thematic screen ranks companies based on overall leadership in the 10 themes that matter most to their industry, generating a leading indicator of future performance.
• The valuation screen ranks our universe of companies within a sector based on selected valuation metrics.
• The risk screen ranks companies within a particular sector based on overall investment risk.

Medical Devices Sector Scorecard – Thematic Screen

For more insights on the sector scorecards, download a free report sample

Scope

• This report is a thematic brief, which identifies those companies most likely to succeed in a world filled with disruptive threats. Inside, we predict how each theme will evolve and identify the leading and disrupting companies.
• The report covers the genomics theme.

Key Highlights

This report explores genomics products in the direct-to-consumer sector, as well as providing an industry analysis on the market and competitive landscape.

Reasons to Buy

• GlobalData’s thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. It has a proven track record of identifying the important themes early, enabling companies to make the right investments ahead of the competition, and secure that all-important competitive advantage.
• Develop and design your corporate strategies through an in-house expert analysis of genomics by understanding the primary ways in which this theme is impacting the healthcare industry.
• Stay up to date on the industry’s major players and where they sit in the value chain.
• Identify emerging industry trends to gain a competitive advantage.